ALTANA Pharma U.S. Appoints Mark Salyer Senior Vice President of Sales and Marketing.
"Mark's significant marketing experience and his broad knowledge of the respiratory markets in particular will be a major asset to us as we develop our new products," said George Cole, president, ALTANA Pharma U.S.
Mr. Salyer comes to ALTANA Pharma U.S. after a 17-year career at GlaxoSmithKline, where he most recently served as Global Commercial Strategy Vice President for the company's respiratory products based in London. In that role, he was responsible for global commercial strategy for current and pipeline products, making it GlaxoSmithKline's most promising product portfolio. Among his other positions at GlaxoSmithKline, he served as the director of marketing of the company's allergy, cardiovascular, asthma, chronic obstructive pulmonary disease and migraine brands in the United States. Mark has a MBA from Duke University.
ALTANA Pharma, formerly Byk Gulden, is an international pharmaceutical company focused primarily on respiratory and gastrointestinal treatments. The company had pharmaceutical sales of $1.4 billion USD in 2001. Its U.S.-based operations, headquartered in Florham Park, New Jersey, were established in 2002. A research-driven pharmaceutical company, ALTANA Pharma invests almost 20 percent of pharmaceutical sales into research. The company's rich history of drug development includes the discovery of the blockbuster proton pump inhibitor pantoprazole, marketed in the United States by Wyeth-Ayerst as Protonix. Going forward, ALTANA Pharma's U.S. operations will market the products developed in its research facilities. ALTANA Pharma's parent company is ALTANA AG, based in Bad Homburg, Germany.
MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X95043258
CONTACT: Jennifer Horowitz of GCI Healthcare, +1-212-537-8126, firstname.lastname@example.org, for ALTANA Pharma U.S.